Instructor of Medicine at @DanaFarber @harvardmed @DFCI_BreastOnc. Breast cancer survivorship, PROs, and supportive care. Alumna of @JohnsHopkinsSPH @UConn
Boston, MA
Joined April 2016
- Tweets180
- Following158
- Followers136
- Likes255
Kate E Dibble, Ph.D. retweeted
New study, led by Dr. Stefania Morganti (@StefiMorganti), now out in @JNCI_Now looking at outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
🔓 pubmed.ncbi.nlm.nih.gov/4218…
✍️@DrBBychkovsky @DrKateDibble @KathrynRuddyMD @ShoshRosenberg @CollinsLauraC @l_schapira @PhilipPoorvu @matteolambe @curijoey @ASCOPres @TariKingMD @nlinmd @judygarber5 @NabihahTayob @stolaney1 @AnnPartridgeMD @FilipaLynce #BreastCancer
Kate E Dibble, Ph.D. retweeted
Check out the recently published Young Women's Breast Cancer Study looking at pregnancy history, recency of childbirth, and outcomes in young women with early-stage #BreastCancer.
👉pubmed.ncbi.nlm.nih.gov/4215…
@GuiNaderMarta @ShoshRosenberg @DrKateDibble @elmayermd @PhilipPoorvu @KathrynRuddyMD @CollinsLauraC @l_schapira @ValenzaCarmine @NabihahTayob @nellage @DrEricWiner @AnnPartridgeMD #AYA
Kate E Dibble, Ph.D. retweeted
New study now out in @ESMO_Open looking at #ScalpCooling outcomes in patients receiving trastuzumab deruxtecan for #MetastaticBreastCancer
🔓pubmed.ncbi.nlm.nih.gov/4225…
@esalehiDNP @elmayermd @DrKateDibble @drsarahsam @NabihahTayob @stolaney1 #MBC #TDXd #BreastCancer #ColdCaps #ADCs
Kate E Dibble, Ph.D. retweeted
#ASCO26 Poster Session | Poster #117 | Long-term safety outcomes of pregnancy among young #BreastCancer survivors: Results from a prospective, multicenter cohort study. #AYA @KimiaSorouriMD @AnnPartridgeMD @ShoshRosenberg @DrKateDibble
Kate E Dibble, Ph.D. retweeted
New @JAMANetworkOpen multicenter study on Extended Endocrine Therapy and Survival for #BreastCancer Subtypes in Premenopausal Patients.
🔓pubmed.ncbi.nlm.nih.gov/4208…
@ValenzaCarmine @monicamilano84 @darioT_ @lorenzoguidimd @bianchitaM @DrKateDibble @elisabettasabet @curijoey @AnnPartridgeMD
Kate E Dibble, Ph.D. retweeted
Secondary outcomes from the YES trial will be presented tomorrow during Rapid Oral Session 1 at #ESMOBreast26. Tune if for an update on the efficacy of an mHealth intervention to address informational needs in adolescent and young adult (#AYA) #BreastCancerSurvivors.
🗓️ Thursday, May 7
⏰ 09:54 - 09:59 CEST (3:54 - 3:59 AM EST)
📍 Berlin Hall
@ShoshRosenberg @AnnPartridgeMD @DrKateDibble
@DrDawnHershman
Kate E Dibble, Ph.D. retweeted
From a #CancerSurvivorship-focused continuing medical education course to practice change implementation: Results of a provider survey
👉pubmed.ncbi.nlm.nih.gov/4173…
@DrKateDibble @AnnPartridgeMD @DrN_CancerPCP @jcansurv
Kate E Dibble, Ph.D. retweeted
📣 Now available as open access on @JCO_ASCO: our analysis on extended endocrine therapy (ET) in premenopausal pts with eBC after 5y of LHRHa.
ascopubs.org/doi/10.1200/JCO…
Which are the pros and cons of extended ET in this setting? 🤔
A thread 🧵1/
@IEOufficiale @DFCI_BreastOnc
Kate E Dibble, Ph.D. retweeted
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study
ascopubs.org/doi/10.1200/JCO…
This cohort analysis evaluated extended endocrine therapy 💊after five years of LHRH agonists in premenopausal women with node-positive, hormone receptor–positive early #BreastCancer . Among 501 patients, extended therapy significantly improved invasive and distant recurrence-free survival compared with stopping therapy.
Five-year invasive disease–free survival was 85% versus 78%. Benefits occurred without increased fractures or major cardiovascular events, supporting extended therapy as a clinically meaningful strategy for high-risk young patients after treatment.
@ValenzaCarmine
@darioT_
@PierPaoloBG
@bianchitaM
@DrKateDibble
@elisabettasabet
@curijoey
@AnnPartridgeMD
Kate E Dibble, Ph.D. retweeted
So honored to work with this extraordinary group!
Happy Holidays from the Dana-Farber breast oncology team @DFCI_BreastOnc coming to you from SABCS 2025!
Kate E Dibble, Ph.D. retweeted
Happy to be part of this incredible family!
❤️❤️
@DFCI_BreastOnc @DanaFarber
@AnnPartridgeMD @GuiNaderMarta @DrKateDibble
Come join our team! Clinical Research Coordinator (CRC) - Young Women's Program (#Boston, Massachusetts) #job social.icims.com/viewjob/pt1… @DFCI_BreastOnc
Kate E Dibble, Ph.D. retweeted
Check out this recent study from @DanaFarber's Young & Strong Program looking at engagement with programmatic electronic communications among young adults with #BreastCancer.
👉pubmed.ncbi.nlm.nih.gov/4032…
@DrKateDibble @KimiaSorouriMD @aj_wiswell @AnnPartridgeMD #AYA #PatientEducation
New pub --> Engagement with Programmatic Electronic Communications among YAs with Breast Cancer published in @MASCC_JSCC. Using @DFCI_BreastOnc Young & Strong program e-comms, we aim to understand engagement & interest by topic offered. rdcu.be/ekNK1 @AnnPartridgeMD
New pub --> Associations between CAHPS scores of patient care experiences and breast cancer survival among senior female survivors: A SEER-CAHPS analysis, the last of my postdoc work! tandfonline.com/doi/full/10.…
Kate E Dibble, Ph.D. retweeted
Congratulations to our @DFCI_BreastOnc providers who were named as #TopDoctors in @BostonMagazine's annual list!
✨Dr. Caroline Block @CBlockMD
✨Dr. Craig Bunnell @bunnell_craig
✨Dr. Harold Burstein @DrHBurstein
✨Dr. Judy Garber @judygarber5
✨Dr. Michael Hassett
✨Dr. Jennifer Ligibel
✨Dr. Nancy Lin @nlinmd
✨Dr. Filipa Lynce @filipalynce
✨Dr. Erica Mayer @elmayermd
✨Dr. Ann Partridge @AnnPartridgeMD
✨Dr. Geoffrey Shapiro @GShapiroMDPhD
✨Dr. Laura Dominici @dr_laurad
✨Dr. Tari King @tarikingmd
✨Dr. Beth Mittendorf @EMittendorfMD
✨Dr. Faina Nakhlis
✨Dr. Esther Rhei
✨Dr. Jennifer Bellon @jenniferbellon2
✨Dr. Laura Warren @lwarrenMD
✨ Dr. Stuart Schnitt @SchnittStuart
Miss you all!!!!
DFCI Young Adult Research Team
What a Dream Team!! ❤️🔥
@AnnPartridgeMD @GuiNaderMarta @DFCI_BreastOnc @DrKateDibble @MeganTesch
Kate E Dibble, Ph.D. retweeted
Unveiling insights into Oncotype DX recurrence scores and their prognostic value in young patients with ER+ breast cancer diagnosed during pregnancy or postpartum
@AnnPartridgeMD
@DFCI_BreastOnc
🚨 Poster from #SABCS2024! Dr @GuiNaderMarta explores how pregnancy influences recurrence scores in HR+/HER2- early breast cancer, uncovering biological insights for future research.
Watch now! 👀 bit.ly/3PyrqMz #MediMix #BreastCancer #Oncology
New protocol pub on the YES intervention published in @BioMedCentral —> link.springer.com/content/pd…
@AnnPartridgeMD @ShoshRosenberg @DFCI_BreastOnc
Kate E Dibble, Ph.D. retweeted
#SABCS24 POSTER SESSION | P2-01-06 | Supportive care concerns of young women living with #MetastaticBreastCancer from an ongoing prospective virtual intervention. @DrKateDibble @ShoshRosenberg @PhilipPoorvu @drsarahsam @nlinmd @AnnPartridgeMD
